JP2010539241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539241A5 JP2010539241A5 JP2010525943A JP2010525943A JP2010539241A5 JP 2010539241 A5 JP2010539241 A5 JP 2010539241A5 JP 2010525943 A JP2010525943 A JP 2010525943A JP 2010525943 A JP2010525943 A JP 2010525943A JP 2010539241 A5 JP2010539241 A5 JP 2010539241A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- inhibitor
- clemizole
- compounds
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical group C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 claims 18
- 229950002020 clemizole Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 150000003839 salts Chemical group 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 241000710781 Flaviviridae Species 0.000 claims 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 2
- 125000002015 acyclic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229940051021 yellow-fever virus Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 208000037404 Central European encephalitis Diseases 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241001466978 Kyasanur forest disease virus Species 0.000 claims 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims 1
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 claims 1
- 241000710884 Powassan virus Species 0.000 claims 1
- 241000907329 Russian Spring-Summer encephalitis virus Species 0.000 claims 1
- 241000710888 St. Louis encephalitis virus Species 0.000 claims 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 C*1CCCC1 Chemical compound C*1CCCC1 0.000 description 5
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97330907P | 2007-09-18 | 2007-09-18 | |
| US60/973,309 | 2007-09-18 | ||
| US8875908P | 2008-08-14 | 2008-08-14 | |
| US61/088,759 | 2008-08-14 | ||
| US9253708P | 2008-08-28 | 2008-08-28 | |
| US61/092,537 | 2008-08-28 | ||
| PCT/US2008/076806 WO2009039248A2 (en) | 2007-09-18 | 2008-09-18 | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539241A JP2010539241A (ja) | 2010-12-16 |
| JP2010539241A5 true JP2010539241A5 (enExample) | 2012-11-08 |
| JP5715820B2 JP5715820B2 (ja) | 2015-05-13 |
Family
ID=40468758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525943A Expired - Fee Related JP5715820B2 (ja) | 2007-09-18 | 2008-09-18 | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9061010B2 (enExample) |
| EP (1) | EP2203168B1 (enExample) |
| JP (1) | JP5715820B2 (enExample) |
| CN (1) | CN101903026B (enExample) |
| AR (1) | AR066165A1 (enExample) |
| AU (1) | AU2008302295B2 (enExample) |
| TW (1) | TW200927102A (enExample) |
| WO (2) | WO2009039246A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9149463B2 (en) | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| JP5715820B2 (ja) * | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
| EP2408449A4 (en) * | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS |
| CN102448457B (zh) * | 2009-03-18 | 2015-09-02 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
| US20100284970A1 (en) * | 2009-04-09 | 2010-11-11 | Auspex Pharmaceuticals, Inc. | Benzimidazole modulators of h1 receptor and/or ns4b protein |
| US20120058085A1 (en) * | 2009-05-15 | 2012-03-08 | Persichetti Rose A | Deuterium Modified Benzimidazoles |
| RU2407738C1 (ru) * | 2009-07-03 | 2010-12-27 | Общество с ограниченной ответственностью "Интеллектуальный Диалог" | Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| EP2491033A4 (en) * | 2009-10-20 | 2013-03-13 | Eiger Biopharmaceuticals Inc | AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION |
| US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| CN107141309A (zh) | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| ES2571741T3 (es) | 2011-03-31 | 2016-05-26 | Bayer Ip Gmbh | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| BR112014013649A2 (pt) | 2011-12-06 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | métodos e agentes para o tratamento de doenças virais e usos dos referidos agentes |
| CN104428293B (zh) * | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
| CN103585616B (zh) * | 2013-08-14 | 2015-05-27 | 南京工业大学 | 二肽类似物的用途 |
| ES2813450T3 (es) | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
| WO2015050998A2 (en) | 2013-10-01 | 2015-04-09 | The Broad Institute, Inc. | Sieve valves, microfluidic circuits, microfluidic devices, kits, and methods for isolating an analyte |
| JP6884703B2 (ja) | 2015-02-25 | 2021-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 障害を治療するための５ｈｔ作動薬 |
| IL300476B2 (en) * | 2015-06-30 | 2024-07-01 | Eiger Group Int Inc | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
| KR102359766B1 (ko) * | 2016-04-01 | 2022-02-07 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체 |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| SG11201808402RA (en) | 2016-04-11 | 2018-10-30 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2018129702A1 (zh) * | 2017-01-13 | 2018-07-19 | 史仅 | 蚊虫叮咬瘙痒寨卡等病毒预防医疗器具 |
| CN108096562B (zh) * | 2017-12-25 | 2021-05-11 | 武汉百药联科科技有限公司 | 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途 |
| WO2019126860A1 (pt) * | 2017-12-29 | 2019-07-04 | Instituto Butantan | Composição farmacêutica para o tratamento de infecção causada por vírus da família flaviviridae, e, uso da composição |
| CN108660253B (zh) * | 2018-04-17 | 2022-05-31 | 广东省妇幼保健院（广东省妇产医院、广东省儿童医院） | 一种基于悬浮微珠阵列系统检测虫媒介病毒的探针、引物、检测试剂盒及检测方法 |
| CN109020895B (zh) * | 2018-08-07 | 2020-04-24 | 枣庄学院 | 一种金属催化的1-苄胺基取代苯并咪唑的合成方法 |
| CN120365272A (zh) | 2018-10-05 | 2025-07-25 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
| WO2020210373A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with etoricoxib |
| WO2021030271A2 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
| US20230241037A1 (en) * | 2020-03-09 | 2023-08-03 | 1Globe Health Institute, Nanjing | Cross-linked medication for treatment of coronaviral infection and method of treatment |
| CN111393372B (zh) * | 2020-05-12 | 2022-08-26 | 中国药科大学 | 一种苯并咪唑衍生物及其制备方法和用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CA3251843A1 (en) * | 2022-05-20 | 2023-11-23 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC STEATOSE AND VIRAL INFECTIONS |
| CN119707828B (zh) * | 2024-12-18 | 2025-12-05 | 江苏天和制药股份有限公司 | 一种盐酸克立咪唑的合成方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2689853A (en) | 1954-09-21 | Certain i | ||
| US2684327A (en) | 1951-11-02 | 1954-07-20 | United Chromium Inc | Bright nickel plating |
| GB1045534A (en) | 1963-02-09 | 1966-10-12 | Schering Ag | New 1-benzyl-5,6-dialkoxy benzimidazoles and a process for their manufacture |
| DE1620450C3 (de) | 1964-07-23 | 1976-01-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 1 - (2- Hydroxybenzyl) -2-piperazinomethylbenzimidazole, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US3428634A (en) | 1965-03-13 | 1969-02-18 | Acraf | 3-tertiary amino alkoxy-1-hydrocarbon indazoles |
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4269835A (en) * | 1979-12-13 | 1981-05-26 | Whittle Barry J | Nasal composition for relieving nasal distress |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| PE27997A1 (es) | 1994-04-29 | 1997-09-20 | Lilly Co Eli | Antagonistas de receptores de taquicininas |
| JP2001513084A (ja) * | 1997-02-25 | 2001-08-28 | ザ ガバメント オブ ザ ユナイテッド ステーツ オブ アメリカ，レプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ | 逆転写酵素の非ヌクレオシド阻害剤としての置換ベンズイミダゾール |
| US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6476062B2 (en) | 2000-03-30 | 2002-11-05 | Schering Corporation | Chemokine receptor antagonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1322325A4 (en) | 2000-07-20 | 2004-09-15 | Merck & Co Inc | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS |
| DE60204224T2 (de) | 2001-03-22 | 2006-02-02 | Ucb S.A. | Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen |
| AR035543A1 (es) * | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2005532991A (ja) | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ |
| TW200902047A (en) | 2003-02-14 | 2009-01-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| PT1611088E (pt) | 2003-04-07 | 2009-09-24 | Pharmacyclics Inc | Hidroxamatos como agentes terapêuticos |
| CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
| WO2005032329A2 (en) * | 2003-08-22 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-hcv agents |
| TW200522932A (en) | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| WO2005051318A2 (en) * | 2003-11-24 | 2005-06-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| BRPI0508107A (pt) | 2004-02-27 | 2007-07-17 | Hoffmann La Roche | derivados de indazol e composições farmacêuticas contendo os mesmos |
| GB0416728D0 (en) | 2004-07-27 | 2004-09-01 | 7Tm Pharma As | Medicinal use of receptor ligands |
| US7790730B2 (en) | 2004-07-27 | 2010-09-07 | Gilead Sciences, Inc. | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
| WO2006135383A2 (en) | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| US20090220583A1 (en) * | 2005-06-09 | 2009-09-03 | Lena Pereswetoff-Morath | Method and composition for treating inflammatory disorders |
| EP1988776B1 (en) | 2006-03-02 | 2012-08-08 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| EP2001480A4 (en) | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| WO2007115077A2 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| JP5715820B2 (ja) | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
-
2008
- 2008-09-18 JP JP2010525943A patent/JP5715820B2/ja not_active Expired - Fee Related
- 2008-09-18 CN CN200880116387XA patent/CN101903026B/zh not_active Expired - Fee Related
- 2008-09-18 AU AU2008302295A patent/AU2008302295B2/en not_active Ceased
- 2008-09-18 AR ARP080104066A patent/AR066165A1/es unknown
- 2008-09-18 WO PCT/US2008/076804 patent/WO2009039246A2/en not_active Ceased
- 2008-09-18 EP EP08832123.7A patent/EP2203168B1/en not_active Not-in-force
- 2008-09-18 TW TW097135844A patent/TW200927102A/zh unknown
- 2008-09-18 WO PCT/US2008/076806 patent/WO2009039248A2/en not_active Ceased
- 2008-09-18 US US12/677,989 patent/US9061010B2/en not_active Expired - Fee Related
- 2008-09-18 US US12/678,014 patent/US8895598B2/en not_active Expired - Fee Related
-
2014
- 2014-09-23 US US14/493,529 patent/US20150044169A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539241A5 (enExample) | ||
| JP2011521903A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| AR066165A1 (es) | Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae | |
| JP2014514308A5 (enExample) | ||
| ES2671478T3 (es) | Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales | |
| ES2680550T3 (es) | Combinaciones de inhibidores del virus de la hepatitis C | |
| RU2011133741A (ru) | Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae | |
| JP2012504126A5 (enExample) | ||
| JP2005524632A5 (enExample) | ||
| JP2008518943A5 (enExample) | ||
| JP2016518359A5 (enExample) | ||
| JP2013521279A5 (enExample) | ||
| JP2013517286A5 (enExample) | ||
| JP2015525220A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2014503516A5 (enExample) | ||
| HRP20140219T1 (hr) | Analozi karba-nukleozida za antivirusno lijeäśenje | |
| JP2010532352A5 (enExample) | ||
| JP2012504632A5 (enExample) | ||
| JP2012513479A5 (enExample) | ||
| JP2011511841A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2005533824A5 (enExample) |